ZAILF Financials: Zai Lab Ltd AI Analysis

Home

Stock

ZAILF

Financials

ZAILF Financial

Zai Lab Ltd

0%

$0

At close: Mar 18, 16:00:00 GMT-4

0%

$0

Post-market: Mar 18, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

EPS (TTM)

Dividend yield

Market Cap

What is ZAILF?

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

ZAILF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	460	460	398	266	215	144
Revenue Growth (YoY)	16%	16%	50%	24%	49%	194%
Cost of Revenue	178	178	147	95	74	52
Gross Profit	281	281	251	170	141	92
Selling, General & Admin	277	277	298	281	258	218
Research & Development	220	220	234	265	286	573
Operating Expenses	498	498	533	547	545	792
Other Non Operating Income (Expenses)	5	5	5	7	3	-5
Pretax Income	-178	-178	-257	-334	-443	-703
Income Tax Expense	-2	-2	0	0	0	0
Net Income	-175	-175	-257	-334	-443	-704
Net Income Growth	-32%	-32%	-23%	-25%	-37%	163%
Shares Outstanding (Diluted)	1,106.17	1,095.31	989.47	966.39	958.06	929.9
Shares Change (YoY)	8%	11%	2%	1%	3%	20%
EPS (Diluted)	-0.16	-0.16	-0.25	-0.34	-0.46	-0.76
EPS Growth	-38%	-38%	-25%	-25%	-39%	117%
Free Cash Flow	-164	-164	-276	-206	-392	-568
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	61.08%	61.08%	63.06%	63.9%	65.58%	63.88%
Operating Margin	-47.17%	-47.17%	-70.6%	-141.35%	-187.9%	-486.11%
Profit Margin	-38.04%	-38.04%	-64.57%	-125.56%	-206.04%	-488.88%
Free Cash Flow Margin	-35.65%	-35.65%	-69.34%	-77.44%	-182.32%	-394.44%
EBITDA	-202	-202	-270	-367	-396	-694
EBITDA Margin	-43.91%	-43.91%	-67.83%	-137.96%	-184.18%	-481.94%
D&A For EBITDA	15	15	11	9	8	6
EBIT	-217	-217	-281	-376	-404	-700
EBIT Margin	-47.17%	-47.17%	-70.6%	-141.35%	-187.9%	-486.11%
Effective Tax Rate	1.12%	1.12%	0%	0%	0%	0%

Follow-Up Questions

What are Zai Lab Ltd's key financial statements?



According to the latest financial statement (Form-10K), Zai Lab Ltd has a total asset of $1,172, Net loss of $-175

What are the key financial ratios for ZAILF?



Zai Lab Ltd's Current ratio is 2.57, has a Net margin is -38.04, sales per share of $0.41.

How is Zai Lab Ltd's revenue broken down by segment or geography?



Zai Lab Ltd largest revenue segment is Innovative Therapies, at a revenue of 3,113,287,942 in the most earnings release.For geography, Greater China and United States is the primary market for Zai Lab Ltd, at a revenue of 3,113,287,942.

Is Zai Lab Ltd profitable?



no, according to the latest financial statements, Zai Lab Ltd has a net loss of $-175

Does Zai Lab Ltd have any liabilities?



yes, Zai Lab Ltd has liability of 456

How many outstanding shares for Zai Lab Ltd?



Zai Lab Ltd has a total outstanding shares of 1,106.38

Zai Lab Ltd (ZAILF) Financial

ZAILF Stock Price Chart